SOX ‐1 antibodies positive Lambert–Eaton myasthenic syndrome with occult small cell lung cancer: A case report
We report a patient with LEMS who was tested positive for SOX-1 antibodies and was definitively diagnosed with SCLC by pathological biopsy after 10 months follow-up. AbstractLambert –Eaton myasthenic syndrome (LEMS) is a rare paraneoplastic neurological syndrome of the neuromuscular transmission. The symptoms often progress slowly and can be misdiagnosed in early stage. Seropositive SOX-1 antibodies are support for the diagnosis of LEMS and have high specificity for small cel l lung cancer (SCLC). In this paper, we report a case of a 56-year-old man with smoking history who was admitted to hospital with progressive mus...
Source: The Clinical Respiratory Journal - March 19, 2024 Category: Respiratory Medicine Authors: Liming Zhao,
Hongyan He,
Weixin Han,
Yizhe Meng,
Lifei Kang,
Yanqiang Chen Tags: BRIEF REPORT Source Type: research
Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses
CONCLUSIONS: RB1 mutations and high fragmentation ratios correlated with early disease recurrence. Analyzing ctDNA could help in predicting early treatment failure and making clinical decisions for high-risk patients.PMID:38496698 | PMC:PMC10938094 | DOI:10.21037/tlcr-23-479 (Source: Cell Research)
Source: Cell Research - March 18, 2024 Category: Cytology Authors: Sehhoon Park Jun-Kyu Kang Naeun Lee Se-Hoon Lee Hwang-Phill Kim Su Yeon Kim Tae-You Kim Hyemin Kim Hyun Ae Jung Jong-Mu Sun Jin Seok Ahn Myung-Ju Ahn Keunchil Park Source Type: research
Systemic immune index predicts tumor-infiltrating lymphocyte intensity and immunotherapy response in small cell lung cancer
CONCLUSIONS: This study provides a method to investigate the prognostic value of overall immune status by combining the PNI with local immune biomarkers in SCLC. The promising clinical application of PNI in efficacy prediction and beneficiary selection for SCLC immunotherapy is also highlighted.PMID:38496688 | PMC:PMC10938096 | DOI:10.21037/tlcr-23-696 (Source: Cell Research)
Source: Cell Research - March 18, 2024 Category: Cytology Authors: Chaoqiang Deng Jiatao Liao Zichen Fu Fangqiu Fu Di Li Yuan Li Jialei Wang Haiquan Chen Yang Zhang Source Type: research
SOX-1 antibodies positive Lambert-Eaton myasthenic syndrome with occult small cell lung cancer: A case report
Clin Respir J. 2024 Mar;18(3):e13740. doi: 10.1111/crj.13740.ABSTRACTLambert-Eaton myasthenic syndrome (LEMS) is a rare paraneoplastic neurological syndrome of the neuromuscular transmission. The symptoms often progress slowly and can be misdiagnosed in early stage. Seropositive SOX-1 antibodies are support for the diagnosis of LEMS and have high specificity for small cell lung cancer (SCLC). In this paper, we report a case of a 56-year-old man with smoking history who was admitted to hospital with progressive muscle weakness of the proximal legs. LEMS was diagnosed by repetitive nerve stimulation (RNS) testing and seropos...
Source: Clinical Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Liming Zhao Hongyan He Weixin Han Yizhe Meng Lifei Kang Yanqiang Chen Source Type: research
SOX-1 antibodies positive Lambert-Eaton myasthenic syndrome with occult small cell lung cancer: A case report
Clin Respir J. 2024 Mar;18(3):e13740. doi: 10.1111/crj.13740.ABSTRACTLambert-Eaton myasthenic syndrome (LEMS) is a rare paraneoplastic neurological syndrome of the neuromuscular transmission. The symptoms often progress slowly and can be misdiagnosed in early stage. Seropositive SOX-1 antibodies are support for the diagnosis of LEMS and have high specificity for small cell lung cancer (SCLC). In this paper, we report a case of a 56-year-old man with smoking history who was admitted to hospital with progressive muscle weakness of the proximal legs. LEMS was diagnosed by repetitive nerve stimulation (RNS) testing and seropos...
Source: Clinical Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Liming Zhao Hongyan He Weixin Han Yizhe Meng Lifei Kang Yanqiang Chen Source Type: research
The Ribonuclease ZC3H12A is required for self-inflicted DNA breaks after DNA damage in small cell lung cancer cells
AbstractRadiotherapy is the first line treatment for small cell lung cancer (SCLC); However, radio-resistance accompanies with the treatment and hampers the prognosis for SCLC patients. The underlying mechanisms remains elusive. Here we discovered that self-inflicted DNA breaks exist in SCLC cells after radiation. Moreover, using nuclease siRNA screening combined with high-content ArrayScan ™ cell analyzer, we identified that Ribonuclease ZC3H12A is required for the self-inflicted DNA breaks after radiation and for SCLC cell survival after DNA damage. ZC3H12A expression was increased in response to DNA damage and when ZC...
Source: Cellular Oncology - March 18, 2024 Category: Cancer & Oncology Source Type: research
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors
CONCLUSION: Our study highlights the predictive value of IHC-classified subtypes and CD8-positive cell infiltration in estimating outcomes for patients with ED-SCLC treated with chemoimmunotherapy as a first-line therapy. These findings have practical implications for daily clinical assessments and treatment decisions.PMID:38483588 | DOI:10.1007/s00432-024-05652-2 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 14, 2024 Category: Cancer & Oncology Authors: Naoki Shijubou Toshiyuki Sumi Terufumi Kubo Kenta Sasaki Tomohide Tsukahara Takayuki Kanaseki Kenji Murata Yoshiko Keira Kotomi Terai Tatsuru Ikeda Yuichi Yamada Hirofumi Chiba Yoshihiko Hirohashi Toshihiko Torigoe Source Type: research
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors
CONCLUSION: Our study highlights the predictive value of IHC-classified subtypes and CD8-positive cell infiltration in estimating outcomes for patients with ED-SCLC treated with chemoimmunotherapy as a first-line therapy. These findings have practical implications for daily clinical assessments and treatment decisions.PMID:38483588 | DOI:10.1007/s00432-024-05652-2 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 14, 2024 Category: Cancer & Oncology Authors: Naoki Shijubou Toshiyuki Sumi Terufumi Kubo Kenta Sasaki Tomohide Tsukahara Takayuki Kanaseki Kenji Murata Yoshiko Keira Kotomi Terai Tatsuru Ikeda Yuichi Yamada Hirofumi Chiba Yoshihiko Hirohashi Toshihiko Torigoe Source Type: research
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors
ConclusionOur study highlights the predictive value of IHC-classified subtypes and CD8-positive cell infiltration in estimating outcomes for patients with ED-SCLC treated with chemoimmunotherapy as a first-line therapy. These findings have practical implications for daily clinical assessments and treatment decisions. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - March 14, 2024 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 1154: The Clinical Value of Pre-Diagnostic Thrombocytosis for the Detection of Lung Cancer in Primary Care
ailey
Thrombocytosis, an elevated platelet count, may suggest a patient has an undiagnosed lung cancer. This primary care study analysed data from English electronic medical records linked to the national cancer registry to understand how often thrombocytosis occurs before a lung cancer diagnosis, whether it is a feature of all the different subtypes of lung cancer, and its relation to the cancer’s stage at diagnosis. We found that the patients with lung cancer were nearly nine times more likely to have thrombocytosis before diagnosis compared to those without cancer. This association was strongest for sq...
Source: Cancers - March 14, 2024 Category: Cancer & Oncology Authors: Melissa Barlow Willie Hamilton Sarah E. R. Bailey Tags: Article Source Type: research
Predicting overall survival and prophylactic cranial irradiation benefit in small-cell lung cancer with CT-based deep learning: A retrospective multicenter study
CONCLUSIONS: The CT-based deep learning model exhibited promising performance in predicting the OS of SCLC patients. The OS signature may aid in individualized treatment planning to select patients who may benefit from PCI.PMID:38479441 | DOI:10.1016/j.radonc.2024.110221 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - March 13, 2024 Category: Radiology Authors: Xiaomin Zheng Kaicai Liu Na Shen Yankun Gao Chao Zhu Cuiping Li Chang Rong Shuai Li Baoxin Qian Jianying Li Xingwang Wu Source Type: research
Predicting overall survival and prophylactic cranial irradiation benefit in small-cell lung cancer with CT-based deep learning: A retrospective multicenter study
CONCLUSIONS: The CT-based deep learning model exhibited promising performance in predicting the OS of SCLC patients. The OS signature may aid in individualized treatment planning to select patients who may benefit from PCI.PMID:38479441 | DOI:10.1016/j.radonc.2024.110221 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - March 13, 2024 Category: Radiology Authors: Xiaomin Zheng Kaicai Liu Na Shen Yankun Gao Chao Zhu Cuiping Li Chang Rong Shuai Li Baoxin Qian Jianying Li Xingwang Wu Source Type: research
Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine
Lung cancer remains the leading cause of cancer-related mortality worldwide accounting for approximately 1.8 million deaths in 2020 [1]. Non-small cell lung cancer (NSCLC) is the predominant histologic subtype, accounting for 85 % of all lung cancer cases in the United States [2]. In comparison, small cell lung cancer (SCLC) represents 15 % of lung cancer cases, occurs almost exclusively in smokers and has the most aggressive clinical course with survival outcomes of 2 to 4 months in untreated patients [3,4]. (Source: Lung Cancer)
Source: Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Josephine A. Taverna, Chia-Nung Hung, Madison Williams, Ryan Williams, Meizhen Chen, Samaneh Kamali, Vaishnavi Sambandam, Cheryl Hsiang-Ling Chiu, Pawel A. Osmulski, Maria E. Gaczynska, Daniel T. DeArmond, Christine Gaspard, Maria Mancini, Meena Kusi, Abh Tags: Review article Source Type: research
TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer
In this study, we have developed a DLL3-TREM1/DAP12 CAR-T (DLL3-DT CAR-T) therapy, demonstrating comparable anti-tumour efficacy against SCLC cells in vitro. In murine xenograft and patient-derived xenograft models, DLL3-DT CAR-T cells exhibited a more robust tumour eradication efficiency than second-generation DLL3-BBZ CAR-T cells. Furthermore, we observed elevated memory phenotypes, induced durable responses, and activation under antigen-presenting cells in DLL3-DT CAR-T cells. Collectively, these findings suggest that DLL3-DT CAR-T cells may offer a novel and potentially effective therapeutic strategy for treating DLL3-...
Source: Immunology - March 12, 2024 Category: Allergy & Immunology Authors: Fengqi Nie Yuli Chen Yanming Hu Peng Huang Xuefei Shi Jingsheng Cai Mantang Qiu Enxiu Wang Kaihua Lu Ming Sun Source Type: research
TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer
In this study, we have developed a DLL3-TREM1/DAP12 CAR-T (DLL3-DT CAR-T) therapy, demonstrating comparable anti-tumour efficacy against SCLC cells in vitro. In murine xenograft and patient-derived xenograft models, DLL3-DT CAR-T cells exhibited a more robust tumour eradication efficiency than second-generation DLL3-BBZ CAR-T cells. Furthermore, we observed elevated memory phenotypes, induced durable responses, and activation under antigen-presenting cells in DLL3-DT CAR-T cells. Collectively, these findings suggest that DLL3-DT CAR-T cells may offer a novel and potentially effective therapeutic strategy for treating DLL3-...
Source: Immunology - March 12, 2024 Category: Allergy & Immunology Authors: Fengqi Nie Yuli Chen Yanming Hu Peng Huang Xuefei Shi Jingsheng Cai Mantang Qiu Enxiu Wang Kaihua Lu Ming Sun Source Type: research
